Skip to content
Open access

Development, Validation, and Clinical Application of a Simultaneous Quantification Method of Seventeen Antituberculosis Drugs in Plasma, Serum, or Saliva Using LC-MS/MS.

Sep 2026 · Therapeutic Drug Monitoring · 0 citations · 34 references
Medicine

TL;DR

This validated LC-MS/MS method allows simultaneous analysis of multiple anti-TB drugs in plasma, serum, and saliva, facilitating clinical and research applications and demonstrated linearity, selectivity, and minimal carry-over.

Abstract

Background

Tuberculosis (TB) remains a global health issue. Treatment involves multiple anti-TB drugs, and pharmacokinetic variability may lead to toxicity or ineffective treatment. Therapeutic drug monitoring may help address these challenges. This study aimed to develop a rapid method to analyze anti-TB drugs in plasma, serum, and saliva.

Methods

A liquid chromatography-tandem mass spectrometry (LC-MS/MS) method was developed for simultaneous quantification of anti-TB drugs in plasma, serum, and saliva. The method was validated according to European Medicines Agency and Food and Drug Administration guidelines, assessing linearity, selectivity, carry-over, accuracy, precision, dilution integrity, matrix effect, recovery, and stability. Performance was evaluated across plasma, serum, and saliva and in an external quality control program.

Results

A method with a runtime of 1.7 minutes was developed to analyze 17 anti-TB drugs and 6 metabolites: (N-desmethyl-)bedaquiline, clofazimine, delamanid, ethambutol, ethionamide, gatifloxacin, (acetyl-)isoniazid, (nor)levofloxacin, linezolid, moxifloxacin, pretomanid, protionamide, pyrazinamide, (desacetyl-)rifabutin, (desacetyl-)rifampicin, (desacetyl-)rifapentine, and tedizolid. The method demonstrated linearity, selectivity, and minimal carry-over. Accuracy and precision were within acceptable limits for all drugs and metabolites, with the largest biases observed for rifabutin (-13.5%) and rifapentine (11.6%). Most drugs were stable, although delamanid and protionamide required immediate processing. All analytes met the precision criteria (CV <15%) in serum and saliva, whereas matrix-specific calibrators were required for some analytes to achieve acceptable accuracy (bias <15%).

Conclusions

This validated LC-MS/MS method allows simultaneous analysis of multiple anti-TB drugs in plasma, serum, and saliva, facilitating clinical and research applications. The method has been successfully applied in clinical practice.

Read PDF

Similar papers

Open access Sep 2026

Simultaneous Quantification of Vedolizumab, Ustekinumab, and Infliximab in Human Serum by LC-MS/MS: Application to Therapeutic Drug Monitoring in Inflammatory Bowel Disease

Purpose With the expanding use of therapeutic monoclonal antibodies (mAbs) in inflammatory bowel disease (IBD), there is a critical need for robust, multiplex analytical tools to support therapeutic drug monitoring (TDM) and pharmacokinetic studies. This study aimed to develop and validate a rapid and sensitive liquid...

Yan-Bao Zhang, Na Wang, Wei-Yang Zheng et al. · 0 citations
Open access Sep 2026

A high-throughput LC-MS/MS assay for therapeutic drug monitoring of combined immunosuppressive and antimicrobial therapy.

The specific SRM transition of 13C₂,d₄-cyclosporine A was characterized for the first time, and a robust LC-MS/MS method was established for the simultaneous quantification of the six target drugs in human whole blood.

Rong-Kun Zhu, Qiu-Yu Liao, Yu-Hong Gan et al. · 0 citations
Open access Sep 2026

LC-triple quadrupole-MS based quantitative analysis of tafenoquine in rat plasma and red blood cells: method development and validation.

BACKGROUND For antimalarial drugs such as Tafenoquine, which preferentially distribute within red blood cells (RBCs), plasma concentrations cannot accurately reflect intracellular drug levels available to exert the therapeutic effect. METHODOLOGY This study aims to establish a sensitive bioanalytical method using LC-...

Akash Rajput, Jinal Ajabiya, S. Powar et al. · 0 citations
#protein folding Open access Sep 2026

Simultaneous quantification of venetoclax, selinexor, voriconazole and fluconazole in human plasma by HPLC-MS/MS and its application in hematological malignancies

Background Venetoclax and selinexor are essential targeted agents for hematological malignancies, but their clinical application is challenged by pronounced ethnic pharmacokinetic differences—especially in Chinese patients—and CYP3A-mediated drug-drug interactions (DDIs) with azole antifungals (voriconazole, fluconazol...

Fei-Fei Han, Yin-Ying Wang, Y. Jian et al. · 0 citations
Open access Sep 2026

LC–MS/MS Quantification of the Anti-Tuberculosis Macrolide Arenicolide A in Rat Plasma: Method Validation and Pharmacokinetic Application

A liquid chromatography–tandem mass spectrometry method for ArA in rat plasma enabled characterization of ArA pharmacokinetics and oral bioavailability and supports a reliable analytical platform for further formulation and preclinical evaluation of ArA as an anti-tuberculosis lead.

Dahan Kim, E. Shin, Seong-Wook Kang et al. · 0 citations
Oct 2026

LC-MS/MS method for quantification of dupilumab in human serum using Protein G enrichment.

The established LC-MS/MS method provides a reliable alternative to immunoassays, with a wide dynamic range suitable for TDM and personalized dose interval adjustments in patients receiving dupilumab.

Kun-Peng Yang, Jian-Hua Wu, Cheng-Ming Yang et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.